• Alcon’s US affiliate, Alcon Laboratories, is on Fortune’s “100 Best Companies to Work For” list for the 10th consecutive year.

• Alma Lasers filed an IPO registration statement with the SEC .

• American Medical Systems reported preliminary 4Q07 sales were up 12.7% compared to 4Q06.

• AngioDynamics’ financial results for 2Q08 showed a 70% increase vs. 2Q07.

• A federal judge ruled that AngioDynamics did not infringe on Diomed’s patent and denied Diomed’s motion for contempt.

• Preliminary 4Q and full-year 2007 financial numbers show that Bausch & Lomb expects 4Q07 net sales to increase about 10% compared to 4Q06.

• Bausch & Lomb plans to buy eyeonics, a privately held ophthalmic medical device company headquartered in Aliso Viejo , CA , that is known for its Crystalens accommodating IOL.

• A new study shows that contact lens solutions – such as Bausch & Lomb’s ReNu or Advanced Medical Optic’s Complete, both of which were recalled due to corneal infections – do not kill biofilms, which may cause such infections. In related news, Bausch & Lomb sued its insurers over their failure to help defend the company against more than 1,000 product liability lawsuits related to B&L’s recalled contact lens solution. B&L also is party to a settlement with the State of New York for environmental cleanup costs at the site of the former Rochester Fire Academy .

• Based on a preliminary review, Biolase expects to report net revenue of more than $20 million for 4Q07, its highest level of quarterly revenue recorded to date.

• Cynosure and its largest shareholder, El.En. SpA, filed a patent infringement lawsuit against CoolTouch.

• Total Vein Solutions, a defendant in Diomed’s effort to enforce its ’777 patent, filed for Chapter 11 bankruptcy protection. In other news, Diomed lost its exclusive right to market Luminetx’ VeinViewer imaging system.

• Novartis’ full-year results for 2007 set a new record. Net sales rose 8%, and net income increased by 66%.

• OccuLogix let go seven top executives.

• Paradigm Medical completed the funding of $1 million through a group of institutional investors, headed by NIR Group.

• QLT slashed its overall headcount by 115 people, or 45% of employees at its Vancouver headquarters and US subsidiaries, including members of its management team.

• Thermage, in an update on its expectations for 4Q07 and the full year ended December 31, said that it now expects revenue for 4Q07 to be about 12% more than 4Q06 revenue of $14.8 million.

• Trimedyne’s financial results for the quarter and fiscal year ended September 30 showed a loss of $324,000 or $0.02 per share on revenues of $5,470,000 for fiscal 2007, compared to a profit of $97,000 or $0.01 per share on revenues of $6,237,000 for fiscal 2006.